Drugs / Dermategrity "Anti-fecal" Barrier Cream
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06221046 | Aug 2026 → Apr 2027 expected | irritant dermatitis | Scotiaderm | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dermategrity "Anti-fecal" Barrier Cream | “Scotiaderm has invented a novel barrier cream (Dermategrity "Anti-fecal" Barrier Cream) with an enhanced formula containing zinc oxide and a natural plant extract that inhibits...” NCT06221046 ↗ |
| Route | Topical | “Scotiaderm Inc. has developed Dermategrity "Anti-fecal" Barrier Cream; a topical formulation of a barrier cream containing zinc oxide with PBIPCs to be used in the treatment of...” NCT06221046 ↗ |